Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Special Report Is Abbott's January Pullback a Good Time to Buy? Reported by Thomas Hughes. Published: 1/24/2026. 
Key Takeaways - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories' (NYSE: ABT) January 2026 pullback has made the stock look attractively valued. The decline appears driven more by market angst than by any fundamental weakness — a knee‑jerk overreaction that has pushed the shares back into what looks like a buy zone. 
A little-known stock could double as Elon Musk prepares to take Starlink public in what may be the biggest IPO in history. This company is a critical supplier to Starlink's fast-growing satellite network. One analyst believes it's positioned for significant upside as the IPO approaches. You can get the ticker symbol free in the first three minutes of a brief video—no credit card required. Watch the video to get the ticker now The zone in question aligns with market action from 2022 to 2024, when Abbott was recovering from its post‑COVID‑19 revenue contraction and institutions were actively accumulating the stock. Abbott Laboratories Growth Accelerates The most that can be said about Abbott Laboratories' Q4 results and guidance is that a few metrics missed market expectations. Still, revenue of $11.46 billion was up 4.5% year over year, margins improved, and adjusted earnings accelerated. Revenue growth missed consensus by several hundred basis points, but margin strength helped offset that shortfall — adjusted earnings per share (EPS) rose about 12%, slightly above consensus. By segment, the results highlighted the resilience of Abbott’s diversified healthcare portfolio. Nutrition and Diagnostics contracted, with Nutrition down nearly 9%, but those declines were offset by solid gains in Established Pharmaceuticals and Med Tech. Established Pharmaceuticals grew about 9%, driven by generics and strength in emerging markets, while Med Tech expanded roughly 12.3%, showing broad-based improvement across its subsegments. Margins improved overall, generally in line with or modestly above forecasts. A favorable product mix, strength in higher‑margin Med Tech, lower COVID‑19 related sales and operational improvements all contributed. Management expects the improvement to continue, forecasting roughly 10% earnings growth in 2026, outpacing revenue growth and supporting the company’s capital return plans. Capital returns are central to the investment case. Abbott is a Dividend King, having increased its payout annually for more than 50 years, and it appears positioned to continue doing so. After the pullback the stock yields about 2.5%, and the payout ratio is under 50% of consensus earnings, leaving ample cash flow for share buybacks — an important offset to dilutive share‑based compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts noted the revenue miss, but there were no major rating or price‑target changes the morning of the earnings release. The prevailing view is that this fundamentally healthy company can continue returning capital while reinvesting in growth, and that the growth runway remains meaningful. The MarketBeat consensus share price target implies as much as ~30% upside from current levels, potentially reaching new highs, while even the low‑end targets suggest some upside potential. Key catalysts include the expanding Med Tech portfolio, the integration of AI across operations and products, margin expansion, and incremental acquisition opportunities. The proposed acquisition of Exact Sciences is an example of how M&A could broaden Abbott’s revenue and profit streams and strengthen its product pipeline. Abbott’s stock decline was sharp and could deepen, but institutional buying throughout 2025 suggests large investors view discounted prices as an opportunity. Initial technical support appears around $105 to $110, though that level is not yet confirmed. The risk is that shares could slip further into the low end of the buy zone before a rebound — potentially testing the mid‑$90s — so investors should weigh that downside against the long‑term case.
| 
